AGR2 and neoplasm: Next, to test if the distribution of AGR2 could modify other components of the secretory pathway, a ratiometric comparison of both BiP and CANX was performed in tumor organoids (Sh-ctl) as compared to tumor organoids silenced for AGR2 (Sh-AGR2) (Figure 5E and Figure 5—figure supplement 1A).